Drug Interactions between Achromycin V and Albenza
This report displays the potential drug interactions for the following 2 drugs:
- Achromycin V (tetracycline)
- Albenza (albendazole)
Interactions between your drugs
No interactions were found between Achromycin V and Albenza. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Achromycin V
A total of 224 drugs are known to interact with Achromycin V.
- Achromycin v is in the drug class tetracyclines.
-
Achromycin v is used to treat the following conditions:
- Acne
- Bacterial Infection
- Bladder Infection
- Bronchitis
- Brucellosis
- Bullous Pemphigoid
- Chlamydia Infection
- Ehrlichiosis
- Epididymitis, Sexually Transmitted
- Gonococcal Infection, Uncomplicated
- Helicobacter Pylori Infection
- Lyme Disease, Arthritis
- Lyme Disease, Carditis
- Lyme Disease, Erythema Chronicum Migrans
- Lyme Disease, Neurologic
- Lymphogranuloma Venereum
- Nongonococcal Urethritis
- Ocular Rosacea
- Ornithosis
- Pelvic Inflammatory Disease
- Pemphigoid
- Pneumonia
- Psittacosis
- Rickettsial Infection
- Syphilis, Early
- Syphilis, Latent
- Tertiary Syphilis
- Upper Respiratory Tract Infection
Albenza
A total of 157 drugs are known to interact with Albenza.
- Albenza is in the drug class anthelmintics.
-
Albenza is used to treat the following conditions:
- Ascariasis
- Capillariasis
- Cutaneous Larva Migrans
- Cysticercus cellulosae
- Echinococcus
- Enterocolitis
- Filariasis, Elephantiasis
- Giardiasis
- Gnathostomiasis
- Hookworm Infection
- Hydatid Disease
- Liver Fluke
- Loiasis
- Microsporidiosis
- Neurocysticercosis
- Pinworm Infection
- Strongyloidiasis
- Trichinosis
- Trichostrongylosis
- Visceral Larva Migrans, Toxicariasis
- Whipworm Infection
Drug and food interactions
tetracycline food
Applies to: Achromycin V (tetracycline)
ADJUST DOSING INTERVAL: Administration with food, particularly dairy products, significantly reduces tetracycline absorption. The calcium content in some foods can form nonabsorbable chelates with tetracycline.
MANAGEMENT: Tetracycline should be administered one hour before or two hours after meals. Because oral tetracycline has caused rare cases of esophagitis and esophageal ulceration, patients should be advised to take tetracycline with a large glass of water while standing or sitting upright and to avoid laying down immediately afterwards.
References (5)
- (2001) "Product Information. Achromycin (tetracycline)." Lederle Laboratories
- (2001) "Product Information. Declomycin (demeclocycline)." Lederle Laboratories
- (2024) "Product Information. Pylera (bismuth subcitrate potassium/metronidazole/tetracycline)." Flynn Pharma Ltd
- (2025) "Product Information. Pylera (bismuth subcitrate potassium/metronidazole/tetracycline)." H2-Pharma LLC
- Laboratoires Juvise Pharmaceuticals (2025) Bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride capsules (Pylera) - product monograph. https://pdf.hres.ca/dpd_pm/00076786.PDF
albendazole food
Applies to: Albenza (albendazole)
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of albendazole, which is rapidly converted by hepatocytes and intestinal mucosal cells into the active metabolite, albendazole sulfoxide (ABZSX), following absorption. The proposed mechanism is stimulation of gastric acid secretion, as the absorption of albendazole is thought to be pH-dependent. According to the product labeling, plasma concentrations of ABZSX are up to 5-fold higher on average when albendazole is administered with a fatty meal (fat content approximately 40 g) compared to administration in the fasted state. In one study of six healthy male volunteers, administration of a single 10 mg/kg oral dose of albendazole in combination with a high-fat meal (57 g fat, 1399 kcal) increased the mean ABZSX peak plasma concentration (Cmax) and systemic exposure (AUC) by 6.5- and 9.4-fold, respectively, and delayed the time to reach Cmax (Tmax) from 2.5 to 5.3 hours compared to administration in the fasted state with water. The elimination half-life was not affected.
MONITOR: Grapefruit juice may increase the oral bioavailability of albendazole, which is rapidly converted by hepatocytes and intestinal mucosal cells into the active metabolite, albendazole sulfoxide (ABZSX), following absorption. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In six healthy male volunteers, administration of a single 10 mg/kg oral dose of albendazole in combination with 250 mL of double-strength grapefruit juice increased the mean ABZSX peak plasma concentration (Cmax) and systemic exposure (AUC) by 3.2- and 3.1-fold, respectively, compared to administration with water. However, because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.
MANAGEMENT: To ensure maximal oral absorption, albendazole should be taken with food. Grapefruit juice may also enhance the oral bioavailability of albendazole.
References (3)
- Awadzi K, Hero M, Opoku NO, Buttner DW, Coventry PA, Prime MA, Orme ML, Edwards G (1994) "The chemotherapy of onchocerciasis XVII. A clinical evaluation of albendazole in patients with onchocerciasis; effects of food and pretreatment with ivermectin on drug response and pharmacokinetics." Trop Med Parasitol, 45, p. 203-8
- (2001) "Product Information. Albenza (albendazole)." SmithKline Beecham
- Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA (2002) "Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability." Am J Trop Med Hyg, 66, p. 260-3
tetracycline food
Applies to: Achromycin V (tetracycline)
GENERALLY AVOID: The bioavailability of oral tetracyclines and iron salts may be significantly decreased during concurrent administration. Therapeutic failure may result. The proposed mechanism is chelation of tetracyclines by the iron cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. In ten healthy volunteers, simultaneous oral administration of ferrous sulfate 200 mg and single doses of various tetracyclines (200 mg to 500 mg) resulted in reductions in the serum levels of methacycline and doxycycline by 80% to 90%, oxytetracycline by 50% to 60%, and tetracycline by 40% to 50%. In another study, 300 mg of ferrous sulfate reduced the absorption of tetracycline by 81% and that of minocycline by 77%. Conversely, the absorption of iron has been shown to be decreased by up to 78% in healthy subjects and up to 65% in patients with iron depletion when ferrous sulfate 250 mg was administered with tetracycline 500 mg. Available data suggest that administration of iron 3 hours before or 2 hours after a tetracycline largely prevents the interaction with most tetracyclines except doxycycline. Due to extensive enterohepatic cycling, iron binding may occur with doxycycline even when it is given parenterally. It has also been shown that when iron is administered up to 11 hours after doxycycline, serum concentrations of doxycycline may still be reduced by 20% to 45%.
MANAGEMENT: Coadministration of a tetracycline with any iron-containing product should be avoided if possible. Otherwise, patients should be advised to stagger the times of administration by at least three to four hours, although separating the doses may not prevent the interaction with doxycycline.
References (11)
- Neuvonen PJ (1976) "Interactions with the absorption of tetracyclines." Drugs, 11, p. 45-54
- Gothoni G, Neuvonen PJ, Mattila M, Hackman R (1972) "Iron-tetracycline interaction: effect of time interval between the drugs." Acta Med Scand, 191, p. 409-11
- Venho VM, Salonen RO, Mattila MJ (1978) "Modification of the pharmacokinetics of doxycycline in man by ferrous sulphate or charcoal." Eur J Clin Pharmacol, 14, p. 277-80
- (2002) "Product Information. Minocin (minocycline)." Lederle Laboratories
- Campbell NR, Hasinoff BB (1991) "Iron supplements: a common cause of drug interactions." Br J Clin Pharmacol, 31, p. 251-5
- Bateman FJ (1970) "Effects of tetracyclines." Br Med J, 4, p. 802
- Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K (1970) "Interference of iron with the absorption of tetracyclines in man." Br Med J, 4, p. 532-4
- Greenberger NJ (1971) "Absorption of tetracyclines: interference by iron." Ann Intern Med, 74, p. 792-3
- Neuvonen PJ, Penttila O (1974) "Effect of oral ferrous sulphate on the half-life of doxycycline in man." Eur J Clin Pharmacol, 7, p. 361-3
- (2018) "Product Information. Seysara (sarecycline)." Allergan Inc
- (2018) "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.